Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12384297 | 0.89 | RAB9A (0.35) | MEN1CYP1A2CYP3A4CYP2C19KMT2A | |
| SCHEMBL11408269 | 0.79 | ALDH1A1 (0.39) | MEN1KMT2ARAB9A | |
| SCHEMBL13634259 | 0.76 | CHRNB2 (0.42) | MEN1CYP3A4KMT2A | |
| SCHEMBL23518518 | 0.75 | ALDH1A1 (0.42) | MEN1CYP1A2CYP3A4CYP2C19KMT2A | |
| SCHEMBL6052875 | 0.75 | CPN1 (0.38) | — | |
| SCHEMBL11339464 | 0.75 | RIPK1 (0.34) | MEN1KMT2ARAB9A | |
| SCHEMBL22030320 | 0.74 | MEN1 (0.40) | MEN1CYP3A4CYP2C19KMT2AFAAH | |
| Hydrochloric Acid SCHEMBL6162375 | 0.73 | CPN1 (0.37) | — | |
| SCHEMBL803092 | 0.72 | CYP1A2 (0.48) | CYP1A2KMT2A | |
| SCHEMBL13040144 | 0.71 | CYP1A2 (0.46) | CYP1A2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291921-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291921-A1 | INTEGRASE INHIBITORS | TYMP, DNTT, PAICS | MEN1 4674/4885CYP1A2 1583/4885CYP3A4 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.